Evidence map›Paper›PMID 37342379›Full record

ArticleAdvanced pharmaceutical bulletin2023

The Effect of miR-4800 Restoration on Proliferation and Migration of Human Breast Cancer Cells

Monireh Khordadmehr, Reyhaneh Matin, Behzad Baradaran, Elham Baghbani, Farinaz Jigari-Asl, Saeed Noorolyai

Open access · diamondAbstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Monireh KhordadmehrDepartment of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, 51665-1647, Tabriz, Iran.ORCID https://orcid.org/0000-0002-4472-3847
Reyhaneh MatinDepartment of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, 51665-1647, Tabriz, Iran.ORCID https://orcid.org/0000-0001-7523-8978
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, 51666-14761, Tabriz, Iran.ORCID https://orcid.org/0000-0002-8642-6795
Elham BaghbaniImmunology Research Center, Tabriz University of Medical Sciences, 51666-14761, Tabriz, Iran.ORCID https://orcid.org/0000-0002-7529-108X
Farinaz Jigari-AslDepartment of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, 51665-1647, Tabriz, Iran.ORCID https://orcid.org/0000-0001-5710-970X
Saeed NoorolyaiImmunology Research Center, Tabriz University of Medical Sciences, 51666-14761, Tabriz, Iran.ORCID https://orcid.org/0000-0001-9686-0854
Tabriz University of Medical Sciences · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MalignancymicroRNAReplacementTherapeutic target

Identifiers

PMID37342379
PMCPMC10278211
OpenAlexW4224016498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.